Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064114480> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2064114480 endingPage "129" @default.
- W2064114480 startingPage "129" @default.
- W2064114480 abstract "Objective: A recent literature review has shown rekindled interest in the use of estramustine phosphate (EMP) inpatients with advanced prostatic cancer. This led us to assess prostate specific antigen (PSA ) response and drug tolerability following EMP therapy inpatients with hormone refractory prostate cancer Patients and Methods: Twenty-five patients with a mean age of 73.5 years (range 49 to 85 years) received EMP for hormone insensitive prostate cancer from January 1996 onwards. They were received at 6 weeks initially followed by 3 monthly intervals to monitor further progression of disease. At each visit clinical examination and blood chemistry (PSA, etc) was done and further investigations, i.e., bone scan, CT scan, etc. were requested if thought necessary. Results: According to the WHO score of pain 71 %found immediate symptomatic relief following EMP treatment but only 29% were pain free after one year PSA level showed a persistent decline of >50% of pre-treatment value in 16 patients (64%) at 6 weeks. However, at 1 year 22% had either a still declining PSA or had reached a stable nadir PSA level while the rest showed rising PSA suggesting insensitivity to EMP. Three out of 5 patients (excluding I patient with intolerance at 2 months) with >80% decrease in PSA at 6 weeks had longer period of progression free interval (1 year in 2 and 2 years in 1 patient). The treatment was generally well tolerated (72%) as only 7 patients had to discontinue EMP because of severe side effects. Conclusions: EMP treatment in patients with hormone escaped prostatic cancer does produce immediate PSA response which is reflected simultaneously in pain improvement in the majority of cases but overall the benefit is shortlived. Patients who have >80% reduction in pre-treatment PSA value at 6 weeks may have longer period of progressionfree intervals. However EMP was generally well tolerated." @default.
- W2064114480 created "2016-06-24" @default.
- W2064114480 creator A5025721428 @default.
- W2064114480 creator A5044838987 @default.
- W2064114480 creator A5055620400 @default.
- W2064114480 creator A5056532100 @default.
- W2064114480 creator A5074497971 @default.
- W2064114480 date "2003-01-01" @default.
- W2064114480 modified "2023-09-26" @default.
- W2064114480 title "Estramustine phosphate in the treatment of hormone escape prostatic carcinoma - a 3 year follow-up" @default.
- W2064114480 doi "https://doi.org/10.4103/0970-1591.37144" @default.
- W2064114480 hasPublicationYear "2003" @default.
- W2064114480 type Work @default.
- W2064114480 sameAs 2064114480 @default.
- W2064114480 citedByCount "0" @default.
- W2064114480 crossrefType "journal-article" @default.
- W2064114480 hasAuthorship W2064114480A5025721428 @default.
- W2064114480 hasAuthorship W2064114480A5044838987 @default.
- W2064114480 hasAuthorship W2064114480A5055620400 @default.
- W2064114480 hasAuthorship W2064114480A5056532100 @default.
- W2064114480 hasAuthorship W2064114480A5074497971 @default.
- W2064114480 hasBestOaLocation W20641144801 @default.
- W2064114480 hasConcept C121608353 @default.
- W2064114480 hasConcept C126322002 @default.
- W2064114480 hasConcept C126894567 @default.
- W2064114480 hasConcept C143998085 @default.
- W2064114480 hasConcept C2776235491 @default.
- W2064114480 hasConcept C2777546739 @default.
- W2064114480 hasConcept C2780201970 @default.
- W2064114480 hasConcept C2994223898 @default.
- W2064114480 hasConcept C71315377 @default.
- W2064114480 hasConcept C71924100 @default.
- W2064114480 hasConceptScore W2064114480C121608353 @default.
- W2064114480 hasConceptScore W2064114480C126322002 @default.
- W2064114480 hasConceptScore W2064114480C126894567 @default.
- W2064114480 hasConceptScore W2064114480C143998085 @default.
- W2064114480 hasConceptScore W2064114480C2776235491 @default.
- W2064114480 hasConceptScore W2064114480C2777546739 @default.
- W2064114480 hasConceptScore W2064114480C2780201970 @default.
- W2064114480 hasConceptScore W2064114480C2994223898 @default.
- W2064114480 hasConceptScore W2064114480C71315377 @default.
- W2064114480 hasConceptScore W2064114480C71924100 @default.
- W2064114480 hasIssue "2" @default.
- W2064114480 hasLocation W20641144801 @default.
- W2064114480 hasOpenAccess W2064114480 @default.
- W2064114480 hasPrimaryLocation W20641144801 @default.
- W2064114480 hasRelatedWork W1991634850 @default.
- W2064114480 hasRelatedWork W2008756773 @default.
- W2064114480 hasRelatedWork W2010645160 @default.
- W2064114480 hasRelatedWork W2043681566 @default.
- W2064114480 hasRelatedWork W2048377455 @default.
- W2064114480 hasRelatedWork W2069156849 @default.
- W2064114480 hasRelatedWork W2069420617 @default.
- W2064114480 hasRelatedWork W2164661085 @default.
- W2064114480 hasRelatedWork W2392413698 @default.
- W2064114480 hasRelatedWork W2118673085 @default.
- W2064114480 hasVolume "19" @default.
- W2064114480 isParatext "false" @default.
- W2064114480 isRetracted "false" @default.
- W2064114480 magId "2064114480" @default.
- W2064114480 workType "article" @default.